Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 1.00 |
| ▸ | CA9 | Q16790 | 16/20 | 1.00 |
| ▸ | CA2 | P00918 | 16/20 | 1.00 |
| ▸ | CA12 | O43570 | 15/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furan SCHEMBL1680246 | 0.92 | CA1 (0.85) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL830181 | 0.85 | CA12 (0.74) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL22273887 | 0.82 | CA12 (0.70) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL831132 | 0.82 | CA12 (0.70) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL1047082 | 0.82 | CA12 (0.70) | CA1CA9CA2CA12KDM4E | |
| Chalcone SCHEMBL22273862 | 0.80 | CA9 (0.64) | CA1CA9CA2CA12 | |
| SCHEMBL852142 | 0.79 | CA12 (0.69) | CA1CA9CA2CA12NPSR1 | |
| SCHEMBL20435590 | 0.79 | KDM4E (0.78) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL27792013 | 0.78 | CA12 (1.00) | CA1CA9CA2CA12NPSR1 | |
| SCHEMBL30719342 | 0.78 | CA12 (0.64) | CA1CA9CA2CA12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730885-B1 | Coumarin derivatives | KING SAUD UNIVERSITY (SA) | 2020-08-04 | — | — | US | claimed |
| CN-117384144-A | Method for preparing coumarin derivative by photocatalysis three components and application thereof | 浙江工业大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-117384144-A | Method for preparing coumarin derivative by photocatalysis three components and application thereof | 浙江工业大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-114751885-B | Coumarin compound containing isopropanolamine structure and preparation method and application thereof | 贵州大学 | 2023-08-08 | — | — | CN | disclosed |
| US-10730885-B1 | Coumarin derivatives | KING SAUD UNIVERSITY (SA) | 2020-08-04 | — | — | US | disclosed |
| US-10730885-B1 | Coumarin derivatives | KING SAUD UNIVERSITY (SA) | 2020-08-04 | — | — | US | disclosed |
| US-9611258-B2 | Dual MEK/PI3K inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2968345-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-01-07 | — | — | US | disclosed |
| WO-2014164942-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-7563902-B2 | Chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060172358-A1 | Novel chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| EP-1651958-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | Roche Diagnostics GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005015215-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| EP-1093379-A2 | USE OF INHIBITORS OF PROTEIN KINASE C EPSILON TO TREAT PAIN | Messing, Robert O. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000001415-A2 | USE OF INHIBITORS OF PROTEIN KINASE C EPSILON TO TREAT PAIN | MESSING ROBERT O (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1994009775-A1 | NOVEL FURO-COUMARINSULFONAMIDES AS PROTEIN KINASE C INHIBITORS | SPHINX PHARMACEUTICALS CORPORATION (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | MAP2K2, MAP2K1, MAP2K7 | CA1 4589/4885CA9 3040/4885CA2 3463/4885 |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | CA1 3859/4885CA9 1884/4885CA2 2552/4885 |
| US-10730885-B1 | Coumarin derivatives | CBR3, KCNH1, CBR1 | CA1 1883/4885CA9 1053/4885CA2 186/4885 |
| US-20060172358-A1 | Novel chemiluminescent compounds and their use | LANCL1, LPO, HLCS | CA1 1660/4885CA9 1112/4885CA2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.